---
title: "Weekly Recap | AEON Biopharma, Inc. -25.82%, consensus target sits above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299508805.md"
description: "AEON Biopharma, Inc. fell 25.82% this week to close at $0.2425. The S&P 500 slipped 0.08%, leaving AEON around 25.74 percentage points behind the benchmark. On Monday, 14 September, the stock pushed as high as $0.3450 before losing ground every day from then on. By Thursday, 17 September, it hit a weekly low of $0.2321. The full-week range was 34.62%."
datetime: "2026-09-19T05:34:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299508805.md)
  - [en](https://longbridge.com/en/news/299508805.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299508805.md)
generator: "portal-rs"
---

# Weekly Recap | AEON Biopharma, Inc. -25.82%, consensus target sits above spot

## The Week

AEON Biopharma, Inc. fell 25.82% this week to close at $0.2425. The S&P 500 slipped 0.08%, leaving AEON around 25.74 percentage points behind the benchmark. On Monday, 14 September, the stock pushed as high as $0.3450 before losing ground every day from then on. By Thursday, 17 September, it hit a weekly low of $0.2321. The full-week range was 34.62%.

## Key Events

The story of the week centres on Monday’s price action. In overnight trading, AEON climbed more than 7% without any matching company announcement. Later that day the stock was up 12% at one point, then the gain narrowed to 9% by mid-afternoon. By the close, it was down 16.98% on heavy volume. While the semiconductor sector was weak across the week, AEON briefly moved higher against that backdrop, with no company-specific release to support the swings.

## Analyst Ratings

Four brokers cover the name: three rate it buy and one rates it overweight. There are no hold, underweight or sell ratings. The consensus rating is strong buy, with a consensus target of $1.525. That sits about 528.87% above the latest price of $0.2425. Targets range from $1.000 to $2.100, showing a wide spread. Within its biotechnology industry, AEON ranks 335th out of 501 names, in the bottom half.

## The Week Ahead

The coming week turns to US macro data. On Tuesday, 22 September, the Richmond Fed composite index is due, with a prior reading of 4. On Wednesday, 23 September, EIA crude oil and Cushing crude oil inventories will be released. Thursday, 24 September, brings initial jobless claims, the current account balance, new home sales and natural gas inventories. There are no company earnings scheduled, but this week’s swings and volume may carry into next week’s trading cues.

## In Short

AEON ends the week with a clear tension. The sell-side consensus is strong buy, and the target price is far above spot. Yet on the latest trading day, medium and small investors were net sellers, and the stock was trading below its 20-day moving average of $0.259. The next question is whether money flows stabilise and whether the macro calendar changes the risk tone.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [AEON.US](https://longbridge.com/en/quote/AEON.US.md)

## Related News & Research

- [AEON Biopharma Posts Updated Investor Presentation Under Reg FD](https://longbridge.com/en/news/302928391.md)
- [AEON Biopharma Presents ABP-450 Development Strategy as Botox Biosimilar](https://longbridge.com/en/news/302923800.md)
- [Can SpaceX Overcome the AI Trade Sell-Off?](https://longbridge.com/en/news/303907541.md)
- [Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop?](https://longbridge.com/en/news/303867113.md)
- [DataMeds AI Subsidiary Corexa Health Secures Supply Agreement for Six Peptides](https://longbridge.com/en/news/303944548.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**